Veradermics (MANE) investor relations material

Executive summary

• Positive topline results from Phase 2/3 Study '302' for VDPHL01 support its potential as the first FDA-approved oral treatment for pattern hair loss in nearly 30 years, with strong intent to prescribe from surveyed healthcare providers and patients.

• Completed IPO in Q1 2026, raising $269.1M net, followed by a $442M follow-on public offering and $30M private placement in May 2026, with total gross proceeds of $766.8M.

• Enrollment completed in Study '304' and ongoing in Study '306', with over 1,000 male and 500 female participants, respectively.

• No products approved or commercialized yet; all revenue to date from equity financings.

Financial highlights

• Net loss of $27.2M for Q1 2026, compared to $12.4M in Q1 2025, driven by increased R&D and G&A expenses.

• Cash, cash equivalents, and marketable securities totaled $390.8M as of March 31, 2026.

• R&D expenses rose to $20.9M (from $11.4M), G&A expenses to $8.9M (from $1.5M) year-over-year.

• Operating cash outflow was $21.2M for Q1 2026, up from $13.3M in Q1 2025.

• Interest and other income totaled $2.6M for Q1 2026.

Outlook and guidance

• Current cash position expected to fund operations and capital expenditures into 2030, supporting multiple Phase 3 readouts and potential commercial launch.

• Expects to release 12-month data from Study '302' and topline data from Study '304' in the second half of 2026.

• Anticipates continued significant operating losses as clinical development and commercialization efforts expand.